Show simple item record

dc.contributor.authorSchulze, Kai
dc.contributor.authorEbensen, Thomas
dc.contributor.authorChandrudu, Saranya
dc.contributor.authorSkwarczynski, Mariusz
dc.contributor.authorToth, Istvan
dc.contributor.authorOlive, Colleen
dc.contributor.authorGuzman, Carlos A
dc.date.accessioned2017-09-27T08:58:10Z
dc.date.available2017-09-27T08:58:10Z
dc.date.issued2017-09-05
dc.identifier.citationBivalent mucosal peptide vaccines administered using the LCP carrier system stimulate protective immune responses against Streptococcus pyogenes infection. 2017, 13 (8):2463-2474 Nanomedicineen
dc.identifier.issn1549-9642
dc.identifier.pmid28887213
dc.identifier.doi10.1016/j.nano.2017.08.015
dc.identifier.urihttp://hdl.handle.net/10033/621124
dc.description.abstractDespite the broad knowledge about the pathogenicity of Streptococcus pyogenes there is still a controversy about the correlate of protection in GAS infections. We aimed in further improving the immune responses stimulated against GAS comparing different vaccine formulations including bis-(3',5')-cyclic dimeric adenosine monophosphate (c-di-AMP) and BPPCysMPEG, a derivative of the macrophage-activating lipopeptide (MALP-2), as adjuvants, respectively, to be administered with and without the universal T helper cell epitope P25 along with the optimized B cell epitope J14 of the M protein and B and T cell epitopes of SfbI. Lipopeptide based nano carrier systems (LCP) were used for efficient antigen delivery across the mucosal barrier. The stimulated immune responses were efficient in protecting mice against a respiratory challenge with a lethal dose of a heterologous S. pyogenes strain. Moreover, combination of the LCP based peptide vaccine with c-di-AMP allowed reduction of antigen dose at the same time maintaining vaccine efficacy.
dc.language.isoenen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.titleBivalent mucosal peptide vaccines administered using the LCP carrier system stimulate protective immune responses against Streptococcus pyogenes infection.en
dc.typeArticleen
dc.contributor.departmentHelmholtz Centre for infection researchGmbH, Inhoffenstr. 7, 38124 Braunschweig, Germany.en
dc.identifier.journalNanomedicine : nanotechnology, biology, and medicineen
refterms.dateFOA2018-11-15T00:00:00Z
html.description.abstractDespite the broad knowledge about the pathogenicity of Streptococcus pyogenes there is still a controversy about the correlate of protection in GAS infections. We aimed in further improving the immune responses stimulated against GAS comparing different vaccine formulations including bis-(3',5')-cyclic dimeric adenosine monophosphate (c-di-AMP) and BPPCysMPEG, a derivative of the macrophage-activating lipopeptide (MALP-2), as adjuvants, respectively, to be administered with and without the universal T helper cell epitope P25 along with the optimized B cell epitope J14 of the M protein and B and T cell epitopes of SfbI. Lipopeptide based nano carrier systems (LCP) were used for efficient antigen delivery across the mucosal barrier. The stimulated immune responses were efficient in protecting mice against a respiratory challenge with a lethal dose of a heterologous S. pyogenes strain. Moreover, combination of the LCP based peptide vaccine with c-di-AMP allowed reduction of antigen dose at the same time maintaining vaccine efficacy.


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
Schulze K et al.pdf
Size:
445.8Kb
Format:
PDF
Description:
original manuscript
Thumbnail
Name:
figures final.ppt
Size:
556Kb
Format:
Microsoft PowerPoint
Description:
figures 1-6 and supplementary ...

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by-nc-sa/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-sa/4.0/